Inhaled dry powder mannitol in cystic fibrosis

Bibliography

• Boyle MP. Adult cystic fibrosis. JAMA 2007;298(15):1787-93
   PubMedGoogle Scholar
• Cystic Fibrosis Foundation Patient Registry 2012 Annual Data Report. Cystic Fibrosis Foundation, Bethesda, MD, USA; 2013
   Google Scholar
• The Canadian Cystic Fibrosis Registry 2012 Annual Report. Cystic Fibrosis Canada, Toronto, Ontario; 2014
   Google Scholar
• Mogayzel PJ Jr, Naureckas ET, Robinson KA, et al. Cystic fibrosis pulmonary guidelines. Chronic medications for maintenance of lung health. Am J Respir Crit Care Med 2013;187(7):680-9
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration. Drugs@FDA. Available from: www.accessdata.fda.gov/scripts/cder/drugsatfda/ [Last accessed 5 April 2004]
   Google Scholar
• Shak S, Capon DJ, Hellmiss R, et al. Recombinant human DNase I reduces the viscosity of cystic fibrosis sputum. Proc Natl Acad Sci USA 1990;87(23):9188-92
   PubMed Web of Science ®Google Scholar
• Fuchs HJ, Borowitz DS, Christiansen DH, et al. Effect of aerosolized recombinant human DNase on exacerbations of respiratory symptoms and on pulmonary function in patients with cystic fibrosis. N Engl J Med 1994;331(10):637-42
   PubMed Web of Science ®Google Scholar
• Suri R, Metcalfe C, Lees B, et al. Comparison of hypertonic saline and alternate-day or daily recombinant human deoxyribonuclease in children with cystic fibrosis: a randomised trial. Lancet 2001;358(9290):1316-21
   PubMed Web of Science ®Google Scholar
• Quan JM, Tiddens HA, Sy JP, et al. A two-year randomized, placebo-controlled trial of dornase alfa in young patients with cystic fibrosis with mild lung function abnormalities. J Pediatr 2001;139(6):813-20
   PubMed Web of Science ®Google Scholar
• Konstan MW, Ratjen F. Effect of dornase alfa on inflammation and lung function: potential role in the early treatment of cystic fibrosis. J Cyst Fibros 2012;11(2):78-83
   PubMed Web of Science ®Google Scholar
• King M, Rubin BK. Pharmacological approaches to discovery and development of new mucolytic agents. Adv Drug Deliv Rev 2002;54(11):1475-90
   PubMedGoogle Scholar
• Elkins MR, Robinson M, Rose BR, et al. A controlled trial of long-term inhaled hypertonic saline in patients with cystic fibrosis. N Engl J Med 2006;354(3):229-40
   PubMed Web of Science ®Google Scholar
• Rosenfeld M, Ratjen F, Brumback L, et al. Inhaled hypertonic saline in infants and children younger than 6 years with cystic fibrosis: the ISIS randomized controlled trial. JAMA 2012;307(21):2269-77
   PubMed Web of Science ®Google Scholar
• Wark P, McDonald VM. Nebulised hypertonic saline for cystic fibrosis. Cochrane Database Syst Rev 2009(2):CD001506
   Google Scholar
• Sawicki GS, Sellers DE, Robinson WM. High treatment burden in adults with cystic fibrosis: challenges to disease self-management. J Cyst Fibros 2009;8(2):91-6
   PubMed Web of Science ®Google Scholar
• Eakin MN, Riekert KA. The impact of medication adherence on lung health outcomes in cystic fibrosis. Curr Opin Pulm Med 2013;19(6):687-91
   PubMed Web of Science ®Google Scholar
• Nasr SZ, Chou W, Villa KF, et al. Adherence to dornase alfa treatment among commercially insured patients with cystic fibrosis. J Med Econ 2013;16(6):801-8
   PubMedGoogle Scholar
• Quittner AL, Zhang J, Marynchenko M, et al. Pulmonary medication adherence and healthcare utilization in cystic fibrosis. Chest 2014. [ Epub ahead of print]
   Google Scholar
• Sawicki GS, Ren CL, Konstan MW, et al. Treatment complexity in cystic fibrosis: trends over time and associations with site-specific outcomes. J Cyst Fibros 2013;12(5):461-7
   PubMed Web of Science ®Google Scholar
• Deis RC, Kearsley MW. Sorbitol and mannitol. In: O’Donnell K, Kearsley MW, editors. Sweeteners and sugar alternatives in food technology. 2nd edition. Wiley-Blackwell; Ames, IA, USA: 2012. p. 331-46
   Google Scholar
• Marshall LF, Smith RW, Rauscher LA, Shapiro HM. Mannitol dose requirements in brain-injured patients. J Neurosurg 1978;48(2):169-72
   PubMedGoogle Scholar
• Weiss DI, Shaffer RN, Wise BL. Mannitol infusion to reduce intraocular pressure. Arch Ophthalmol 1962;68:341-7
   PubMedGoogle Scholar
• Daviskas E, Anderson SD. Hyperosmolar agents and clearance of mucus in the diseased airway. J Aerosol Med 2006;19(1):100-9
   PubMedGoogle Scholar
• Daviskas E, Anderson SD, Jaques A, Charlton B. Inhaled mannitol improves the hydration and surface properties of sputum in patients with cystic fibrosis. Chest 2010;137(4):861-8
   PubMedGoogle Scholar
• Therapeutic Goods Administration. Bronchitol product information. 2014. Available from: www.ebs.tga.gov.au/ebs/picmi/picmirepository.nsf/pdf?OpenAgent&id=CP-2011-PI-02102-3 [Last accessed 6 April 2014]
   Google Scholar
• Aitken ML, Bellon G, De Boeck K, et al. Long-term inhaled dry powder mannitol in cystic fibrosis: an international randomized study. Am J Respir Crit Care Med 2012;185(6):645-52
   PubMed Web of Science ®Google Scholar
• Leuppi JD. Bronchoprovocation tests in asthma: direct versus indirect challenges. Curr Opin Pulm Med 2014;20(1):31-6
   PubMed Web of Science ®Google Scholar
• Bilton D, Daviskas E, Anderson SD, et al. Phase 3 randomized study of the efficacy and safety of inhaled dry powder mannitol for the symptomatic treatment of non-cystic fibrosis bronchiectasis. Chest 2013;144(1):215-25
   PubMed Web of Science ®Google Scholar
• Teper A, Jaques A, Charlton B. Inhaled mannitol in patients with cystic fibrosis: A randomised open-label dose response trial. J Cyst Fibros 2011;10(1):1-8
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Aridol clinical pharmacology biopharmaceutics review(s). 2009. Available from: www.accessdata.fda.gov/drugsatfda_docs/nda/2010/022368Orig1s000ClinPharmR.pdf [Last accessed 6 April 2014]
   Google Scholar
• Australian Government Department of Health and Ageing, Therapeutic Goods Administration. Australian Public Assessment Report for Mannitol. 2011. Available from: www.tga.gov.au/pdf/auspar/auspar-bronchitol.pdf [Last accessed 6 April 2014]
   Google Scholar
• Robinson M, Daviskas E, Eberl S, et al. The effect of inhaled mannitol on bronchial mucus clearance in cystic fibrosis patients: a pilot study. Eur Respir J 1999;14(3):678-85
   PubMed Web of Science ®Google Scholar
• Jaques A, Daviskas E, Turton JA, et al. Inhaled mannitol improves lung function in cystic fibrosis. Chest 2008;133(6):1388-96
   PubMed Web of Science ®Google Scholar
• Minasian C, Wallis C, Metcalfe C, Bush A. Comparison of inhaled mannitol, daily rhDNase and a combination of both in children with cystic fibrosis: a randomised trial. Thorax 2010;65(1):51-6
   PubMedGoogle Scholar
• Bilton D, Robinson P, Cooper P, et al. Inhaled dry powder mannitol in cystic fibrosis: an efficacy and safety study. Eur Respir J 2011;38(5):1071-80
   PubMed Web of Science ®Google Scholar
• Bilton D, Bellon G, Charlton B, et al. Pooled analysis of two large randomised phase III inhaled mannitol studies in cystic fibrosis. J Cyst Fibros 2013;12(4):367-76
   PubMed Web of Science ®Google Scholar
• Medicines and Healthcare products Regulatory Agency. Mannitol drug analysis print. 2013. Available from: www.mhra.gov.uk/home/groups/public/documents/sentineldocuments/dap_10376772136727856.pdf [Last accessed 6 April 2014]
   Google Scholar
• Committee for Medicinal Products for Human Use (CHMP). CHMP summary of positive opinion for Bronchitol. 2011. Available from: www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/001252/WC500116889.pdf [Last accessed 6 April 2014]
   Google Scholar
• ClinicalTrials.gov. Crossover trial determining the efficacy of dry powder mannitol to improve lung function in subjects aged 6-17 years. 2013. Available from: http://clinicaltrials.gov/ct2/show/NCT01883531 [Last accessed 6 April 2014]
   Google Scholar
• Morgan WJ, Butler SM, Johnson CA, et al. Epidemiologic study of cystic fibrosis: design and implementation of a prospective, multicenter, observational study of patients with cystic fibrosis in the U.S. and Canada. Pediatr Pulmonol 1999;28(4):231-41
   PubMed Web of Science ®Google Scholar
• Saiman L, Marshall BC, Mayer-Hamblett N, et al. Azithromycin in patients with cystic fibrosis chronically infected with Pseudomonas aeruginosa: a randomized controlled trial. JAMA 2003;290(13):1749-56
   PubMed Web of Science ®Google Scholar
• Cheer SM, Waugh J, Noble S. Inhaled tobramycin (TOBI): a review of its use in the management of Pseudomonas aeruginosa infections in patients with cystic fibrosis. Drugs 2003;63(22):2501-20
   PubMed Web of Science ®Google Scholar
• Waters V, Stanojevic S, Atenafu EG, et al. Effect of pulmonary exacerbations on long-term lung function decline in cystic fibrosis. Eur Respir J 2012;40(1):61-6
   PubMed Web of Science ®Google Scholar
• Sanders DB, Bittner RC, Rosenfeld M, et al. Failure to recover to baseline pulmonary function after cystic fibrosis pulmonary exacerbation. Am J Respir Crit Care Med 2010;182(5):627-32
   PubMed Web of Science ®Google Scholar